棕榈酰乙醇胺(PEA),内源性脂肪酸酰胺,已被证明与细胞核中的受体结合-过氧化物酶体增殖物激活受体-并执行与慢性和神经性疼痛和炎症相关的多种生物学功能,正如临床试验所证明的那样。这些包括周围神经病变,如糖尿病性神经病,化疗诱导的周围神经病变,腕管综合征,坐骨神经疼痛,骨关节炎,腰痛,背部手术失败综合征,牙疼,中风和多发性硬化症的神经性疼痛,慢性盆腔疼痛,带状疱疹后遗神经痛,和阴道疼痛。可能是由于PEA是一种内源性调节剂,也是食品中的一种化合物,比如鸡蛋和牛奶,没有严重副作用的报道,也没有药物相互作用。本文提供了一系列案例,描述了PEA在治疗与标准疗法反应不佳的慢性疼痛相关的各种综合征中的应用,潜在疗效和安全性。
Palmitoylethanolamide (PEA), an endogenous fatty acid amide, has been demonstrated to bind to a receptor in the cell nucleus - the peroxisome proliferator-activated receptor - and performs a great variety of biological functions related to chronic and neuropathic pain and inflammation, as has been demonstrated in clinical trials. These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia, and vaginal pains. Probably due to the fact that PEA is an endogenous modulator as well as a compound in food, such as eggs and milk, no serious side effects have been reported, nor have drug-drug interactions. This article presents a
case series describing the application and potential efficacy and safety of PEA in the treatment of various syndromes associated with chronic pain that is poorly responsive to standard therapies.